Table 3.

Association between daily cholecalciferol (n = 165,588) or calcifediol dose (n = 132,590) and COVID-19 outcomes

Outcome	Cholecalciferol dose, daily mean (SD) μg	Univariate analysis3		Multivariate analysis4		Calcifediol dose, daily mean (SD) μg	Univariate analysis3		Multivariate analysis4
		HR (CI 95%)5	p	HR (CI 95%)5	p		HR (CI 95%)5	p	HR (CI 95%)5	p
SARS-CoV2 infection1, n (%)
Yes	15.4 (11.9)	1.00 (0.98–1.03)	0.729	0.97 (0.95–0.99)	0.005	19.8 (10.0)	1.06 (1.03–1.09)	< 0.001	–	NS
No	15.3 (12.3)					19.3 (8.5)
Severe COVID-192, n (%)
Yes	15.1 (12.3)	0.99 (0.94–1.04)	0.986	0.92 (0.87–0.97)	0.002	20.1 (9.1)	1.06 (1.02–1.09)	0.002	–	NS
No	15.3 (12.3)					19.3 (8.6)
COVID-19 mortality, n (%)
Yes	15.0 (11.8)	0.98 (0.93–1.03)	0.442	0.90 (0.85–0.96)	0.001	20.2 (9.4)	1.06 (1.02–1.11)	0.002	–	NS
No	15.4 (12.3)					19.3 (8.6)

¹Positive PCR or clinical diagnosis of SARS-CoV2 infection

²Composite outcome of need for non-invasive mechanical ventilation, orotracheal intubation, mechanical ventilation, intensive care unit admission or death

³Unadjusted Cox regression analysis

⁴Cox regression analysis controlling for all covariates

⁵Ratios are calculated for every 10 µg increase in the mean daily cholecalciferol or calcifediol dose